Chronic Conditions

Wegovy®

starting at $1,599.99

Wegovy is used for chronic weight management in individuals with a BMI of > 30 kg/m2, or a BMI of > 27 kg/m2 and weight associated comorbidities, including high cholesterol, diabetes, and high blood pressure. Wegovy is injected under the skin once weekly with a total duration of therapy of up to 16 weeks. Therapy can be discontinued sooner if desirable results are achieved. Follow package instructions upon receiving the product. *This product is not eligible for discount*

Wegovy is a once weekly semaglutide injection used for long term weight loss for individuals with a BMI of >30 kg/m2, or a BMI of >27 kg/m2 with weight associated health condition

Wegovy is used in combination with diet and exercise intervention

Dosing begins at 0.25 mg once weekly for 4 weeks and is increased every 3 to 4 weeks

Dose titration can be delayed based on tolerance

Treatment occurs over the course of 16 weeks and continues thereafter with weekly injections

Consider discontinuation of the product if at least 5% of body weight is lost

Must be stored at refrigerated temperatures (2°C to 8°C) or at room temperature for up to 28 days (46°F to 86°F)

HSA/FSA Eligible

Wegovy®

H&P Certification

Tell us about yourself.

“You need to carefully review and make sure you can agree to each statement. If there are questions, a doctor will be in touch after checkout.”

Wegovy®

Wegovy is used for chronic weight management in individuals with a BMI of > 30 kg/m2, or a BMI of > 27 kg/m2 and weight associated comorbidities, including high cholesterol, diabetes, and high blood pressure. Wegovy is injected under the skin once weekly with a total duration of therapy of up to 16 weeks. Therapy can be discontinued soon if desirable results are achieved. Follow package instructions upon receiving the product.

By clicking the “I Agree” button below, you certify under penalty of perjury that the following statements are true and correct and understand that a medical provider will rely on the truthfulness of your statements when determining whether a prescription is warranted and appropriate.

I agree that I:

am 18 years or older
have not had a hypersensitivity reaction to Wegovy, semaglutide, or any component of the formulation
do not have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)
do not have Type 1 diabetes or diabetic ketoacidosis (DKA)
understand psychiatric effects have occurred, such as suicidal thoughts, with other medications for weight management
have not had bariatric surgery
understand this medication may slow gastric emptying which can alter the absorption of other medications
understand this medication has shown incidence of acute kidney injury, diabetic retinopathy, gallbladder disease, gastrointestinal side effects, and pancreatitis
am not pregnant or breastfeeding
do not have liver (hepatic) or kidney (renal) impairment
understand this is not a comprehensive list of precautions, risks, side effects, or details about taking this medication
understand that drug interactions have not been reviewed against the other medications, supplements, or herbal products I may be taking unless also filled by TelyRx

understand that TelyRx LLC does not provide medical care and the providers who use TelyRx to provide telehealth services (“Telehealth Providers”) should not replace your primary provider.
understand that the Telehealth Providers are not able to: (1) monitor ongoing health or lab values for side effects or efficacy, (2) observe how you (or your pet) tolerate any prescribed treatment, or (3) determine if the prescribed treatment is working as intended and assume any risks associated with this modality of care and waive any claim I may have in the future against TelyRx and/or the Telehealth Providers.
understand that by using this site, I have created a patient-client-doctor relationship and I am being directed by the Telehealth Providers to consult my primary provider soon after beginning any treatment prescribed by the Telehealth Providers.
understand that this is a supplemental mode of care for your convenience and the Telehealth Providers are not to be used, or relied on, as a replacement for in-person follow-up visits or interactions with your primary provider.

I agree that all statements above are true and my physician visit is complete.

Cancel

Web-form is not active.

Skip to the end of the images gallery

For illustration purposes only. Product appearance may vary based on manufacturer availability.

Skip to the beginning of the images gallery

Wegovy® Medication Description
Wegovy® injection (semaglutide) is a prescription medication approved for chronic weight management in adults and certain adolescents with obesity, or in adults who are overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Wegovy is part of a treatment plan that includes reduced-calorie diet and increased physical activity.

Wegovy works by mimicking the GLP-1 (glucagon-like peptide-1) hormone, which helps regulate appetite and food intake. By slowing digestion, reducing hunger, and promoting a sense of fullness, Wegovy can help patients lower calorie intake and support meaningful, sustained weight loss when combined with healthy lifestyle changes.

How to Use
- Wegovy® is typically prescribed as a once-weekly subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm.
- Treatment is usually started at a lower dose and gradually increased over several months to improve tolerability.
- A common dosing approach begins with 0.25 mg once weekly, with stepwise increases until reaching the maintenance dose of 2.4 mg once weekly, as directed by your healthcare provider.
- Injections are given on the same day each week, with or without food.
- Injection sites should be rotated each week, and a new needle should be used for every injection.
- If a dose is missed, your healthcare provider will advise whether to take it when remembered or wait until the next scheduled dose.
Black Box Warning

Wegovy® (semaglutide) carries a boxed warning regarding the risk of thyroid C-cell tumors. It should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Patients should promptly report symptoms such as a lump in the neck, hoarseness, difficulty swallowing, or shortness of breath.

Important Notes and Warnings
- The most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, especially during dose escalation.
- Serious but less common risks include pancreatitis, gallbladder disease, low blood sugar (particularly if used with diabetes medications), and kidney problems.
- Wegovy should not be used together with other semaglutide products or other GLP-1 receptor agonists.
- Not recommended in pregnancy; treatment should be discontinued at least 2 months before a planned pregnancy.
- Inform your healthcare provider of all medications you are taking, as Wegovy may delay gastric emptying and affect absorption of oral drugs.
- Wegovy is intended for long-term use as part of a comprehensive weight management program.
Storage
- Store Wegovy pens in the refrigerator between 36°F to 46°F (2°C to 8°C) before first use.
- After first use, pens may be kept at room temperature (59°F to 86°F / 15°C to 30°C) or refrigerated, and must be used within 28 days.
Wegovy® Side Effects

Wegovy side effects include injection site reactions, constipation, diarrhea, and stomach pain.
Consumer Information Use and Disclaimer

This information should not be used to decide whether or not to take this medicine or any other medicine. Only a healthcare provider has the knowledge and training to decide which medicines are right for you. TelyRx does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education materials and is not intended to be comprehensive. This limited summary does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you may receive from your healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please review the entire patient education information you receive with the medication.